Lung cancer combo trial halted after just one patient
NCT ID NCT04786093
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested the drug durvalumab (Imfinzi) combined with two different schedules of stereotactic radiation for people with advanced non-small cell lung cancer. The goal was to see if the combination improved quality of life and controlled tumor growth. However, the trial was terminated early after enrolling only one participant, so no meaningful conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Durvalumab (a drug that helps the immune system fight cancer) and stereotactic radiation therapy (precise, high-dose radiation)
- What this could lead to
- If it had succeeded, this could have pointed toward a way to improve quality of life and control tumors in advanced lung cancer using a combination of immunotherapy and targeted radiation.
- What could go wrong
- The trial was terminated early with only 1 participant, so we have very little data. It is unclear if the combination works better than standard treatment, and there may be side effects from both the drug and radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?